Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 12/20 | 0.75 |
| ▸ | DNMT1 | P26358 | 10/20 | 0.75 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20113792 | 0.92 | DNMT3A (0.64) | DNMT3ADNMT1HRH4HRH3PDE5A | |
| SCHEMBL18103395 | 0.89 | DNMT3A (0.59) | DNMT3ADNMT1HRH4PDE5AHTR3A | |
| SCHEMBL18095968 | 0.88 | DNMT3A (0.80) | DNMT3ADNMT1HRH3 | |
| SCHEMBL16586019 | 0.86 | DNMT3A (1.00) | DNMT3ADNMT1HRH3 | |
| SCHEMBL18103385 | 0.84 | DNMT3A (0.71) | DNMT3ADNMT1HRH3 | |
| SCHEMBL18095983 | 0.83 | DNMT3A (0.63) | DNMT3ADNMT1 | |
| SCHEMBL16586653 | 0.82 | DNMT3A (0.90) | DNMT3ADNMT1HRH3 | |
| SCHEMBL16586016 | 0.82 | DNMT3A (0.91) | DNMT3ADNMT1HRH3 | |
| SCHEMBL16596234 | 0.81 | DNMT3A (1.00) | DNMT3ADNMT1HRH3 | |
| SCHEMBL17996203 | 0.81 | DNMT3A (0.88) | DNMT3ADNMT1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-10-22 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-05-03 | — | — | US | disclosed |
| EP-3277676-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS | Pierre Fabre Médicament (FR) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016151144-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016151144-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS | PIERRE FABRE MEDICAMENT (FR) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450299-B2 | Substituted quinazoline derivatives as DNA methyltransferase inhibitors | DNMT1, DNMT3A, DNMT3B | DNMT3A 2/4885DNMT1 1/4885HRH4 3065/4885 |
| US-20180118717-A1 | Substituted Quinazoline Derivatives as DNA Methyltransferase Inhibitors | DNMT1, DNMT3A, DNMT3B | DNMT3A 2/4885DNMT1 1/4885HRH4 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.